All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression kidney transplant recipients obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline solid cancer solid organ transplant recipients subjects at risk
vaccines in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias confirmed COVID (any severity)detailed results Kislaya, 2022 0.36 [0.20; 0.64]
Nguyen, 2022 0.99 [0.88; 1.11]
0.62 [0.23 ; 1.67 ] Kislaya, 2022, Nguyen, 2022 2 91% NA not evaluable hospitalizationdetailed results Botton (EPI-PHARE), 2022 6.70 [4.60; 9.76]
6.70 [4.60 ; 9.76 ] Botton (EPI-PHARE), 2022 1 0% NA not evaluable adverse eventsdetailed results Com-COV, 2021 1.14 [0.78; 1.66]
Com-COV2, 2022 (REV) 0.87 [0.63; 1.22]
0.98 [0.76 ; 1.27 ] Com-COV, 2021, Com-COV2, 2022 (REV) 2 8% 1,535 NA not evaluable intracranial hemorrhage detailed results Com-COV, 2021 1.01 [0.02; 51.28]
Com-COV2, 2022 (REV) 0.20 [0.00; 10.18]
Li J, 2022 1.03 [0.02; 52.46]
MixNMatch Study, 2021 2.05 [0.04; 103.83]
0.81 [0.11 ; 5.77 ] Com-COV, 2021, Com-COV2, 2022 (REV), Li J, 2022, MixNMatch Study, 2021 4 0% 2,291 NA not evaluable ischemic strokedetailed results Com-COV, 2021 1.01 [0.02; 51.28]
Com-COV2, 2022 (REV) 0.40 [0.01; 12.06]
Li J, 2022 1.03 [0.02; 52.46]
MixNMatch Study, 2021 2.05 [0.04; 103.83]
0.90 [0.14 ; 5.94 ] Com-COV, 2021, Com-COV2, 2022 (REV), Li J, 2022, MixNMatch Study, 2021 4 0% 2,291 NA not evaluable Myocardial infarction detailed results Com-COV, 2021 1.01 [0.02; 51.28]
Com-COV2, 2022 (REV) 0.10 [0.00; 3.00]
Li J, 2022 1.03 [0.02; 52.46]
MixNMatch Study, 2021 2.05 [0.04; 103.83]
Reindl-Schwaighofer, 2021 2.03 [0.07; 61.21]
0.79 [0.15 ; 4.09 ] Com-COV, 2021, Com-COV2, 2022 (REV), Li J, 2022, MixNMatch Study, 2021, Reindl-Schwaighofer, 2021 5 0% 2,492 NA not evaluable pulmonary embolismdetailed results Com-COV, 2021 1.01 [0.02; 51.28]
Com-COV2, 2022 (REV) 0.20 [0.00; 10.18]
Li J, 2022 1.03 [0.02; 52.46]
MixNMatch Study, 2021 2.05 [0.04; 103.83]
0.81 [0.11 ; 5.77 ] Com-COV, 2021, Com-COV2, 2022 (REV), Li J, 2022, MixNMatch Study, 2021 4 0% 2,291 NA not evaluable serious adverse events (SAE), anydetailed results Reindl-Schwaighofer, 2021 1.53 [0.25; 9.36]
1.53 [0.25 ; 9.36 ] Reindl-Schwaighofer, 2021 1 0% 201 NA not evaluable venous thromboembolism detailed results Com-COV2, 2022 (REV) 0.40 [0.01; 12.06]
Li J, 2022 1.03 [0.02; 52.46]
Reindl-Schwaighofer, 2021 2.03 [0.07; 61.21]
0.94 [0.12 ; 7.29 ] Com-COV2, 2022 (REV), Li J, 2022, Reindl-Schwaighofer, 2021 3 0% 1,572 NA not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-14 13:37 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 89
- treatments: 551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803
- roots T: 290
